United Kingdom· GB-APID-45290111000001108
Beyfortus 100mg/1ml solution for injection pre-filled syringes
A nirsevimab product containing nirsevimab, registered in United Kingdom by Sanofi. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Nirsevimab is registered in 14 of 19 countries.
Countries holding a registration under ATC J06BD08 (nirsevimab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Nirsevimab · ATC J06BD08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Nirsevimab
- Manufacturer
- Sanofi
- Country
- United Kingdom (GB)
- ATC code
- J06BD08
- ATC class
- Nirsevimab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5000283662785
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nirsevimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBEYFORTUSSanofi Winthrop Industrie, Gentilly
- SpainBEYFORTUS 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADASanofi Winthrop Industrie
- IcelandBeyfortusSanofi Winthrop Industrie
- NorwayBeyfortusSanofi Winthrop Industrie
- PolandBeyfortusSanofi Winthrop Industrie
- SwitzerlandBeyfortus
- SwedenBeyfortus 100 mg Injektionsvätska, lösning i förfylld sprutaSanofi Winthrop Industrie
- United StatesBEYFORTUSSanofi Vaccines US Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Beyfortus
- Liechtenstein · Beyfortus
- Norway · Beyfortus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da74bfa1-5584-41f2-8973-3eac3f54c433 GET /v1/drugs/da74bfa1-5584-41f2-8973-3eac3f54c433?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45290111000001108",
"desc": "Beyfortus 100mg/1ml solution for injection pre-filled syringes (Sanofi)",
"form": "Solution for injection",
"vpid": "45294611000001107",
"source": "dmd",
"vtm_id": "45291811000001109",
"strength": "100 mg",
"substance": "Nirsevimab",
"ingredient": "Nirsevimab",
"supplier_code": "9190711000001101"
}See everything about nirsevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.